ELOX

SEC source: 0001209191-18-021395 · doc4.xml · nonDerivative · entry 5

Kariv Tomer · CIK 0001568077 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 789,878

F2 · ownership.nature: Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021395 · doc4.xml · nonDerivative · entry 4

Kariv Tomer · CIK 0001568077 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 384,544

F1 · ownership.nature: Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. Mr. Kariv is a Managing Partner of Management 4. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021389 · doc4.xml · nonDerivative · entry 6

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax IV GP L.P. · CIK 0001726353 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 427,063

F3 · ownership.nature: Represents shares of the Issuer held by Pontifax (China) IV L.P. ("China IV"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021389 · doc4.xml · nonDerivative · entry 5

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax IV GP L.P. · CIK 0001726353 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 789,878

F2 · ownership.nature: Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021389 · doc4.xml · nonDerivative · entry 4

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax IV GP L.P. · CIK 0001726353 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 384,544

F1 · ownership.nature: Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021336 · doc4.xml · nonDerivative · entry 1

Avnur Zafrira · CIK 0001726049 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By: Spouse's IRA

Disclosed balance after: 263

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.59 to $7.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

SEC source: 0001209191-18-021398 · doc4.xml · nonDerivative · entry 3

Nussbaum Ran · CIK 0001609805 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 425,463

F3 · ownership.nature: Represents shares of the Issuer held by Pontifax (China) IV, L.P. ("China IV"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021398 · doc4.xml · nonDerivative · entry 2

Nussbaum Ran · CIK 0001609805 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 786,919

F2 · ownership.nature: Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021398 · doc4.xml · nonDerivative · entry 1

Nussbaum Ran · CIK 0001609805 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 383,103

F1 · ownership.nature: Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. Mr. Nussbaum is a Managing Partner of Management 4. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021395 · doc4.xml · nonDerivative · entry 3

Kariv Tomer · CIK 0001568077 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 425,463

F3 · ownership.nature: Represents shares of the Issuer held by Pontifax (China) IV, L.P. ("China IV"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021395 · doc4.xml · nonDerivative · entry 2

Kariv Tomer · CIK 0001568077 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 786,919

F2 · ownership.nature: Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021395 · doc4.xml · nonDerivative · entry 1

Kariv Tomer · CIK 0001568077 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 383,103

F1 · ownership.nature: Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. Mr. Kariv is a Managing Partner of Management 4. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021389 · doc4.xml · nonDerivative · entry 3

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax IV GP L.P. · CIK 0001726353 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 425,463

F3 · ownership.nature: Represents shares of the Issuer held by Pontifax (China) IV L.P. ("China IV"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021389 · doc4.xml · nonDerivative · entry 2

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax IV GP L.P. · CIK 0001726353 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 786,919

F2 · ownership.nature: Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001209191-18-021389 · doc4.xml · nonDerivative · entry 1

Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner

Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner

Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner

Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner

Pontifax IV GP L.P. · CIK 0001726353 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pontifax Investment Fund

Disclosed balance after: 383,103

F1 · ownership.nature: Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

SEC source: 0001144204-18-002949 · tv483653_4.xml · derivative · entry 1

Huertas Pedro · CIK 0001389517 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2028-01-15

F1 · derivative.exercise_date: The option vests over a four-year period commencing on January 15, 2018 in sixteen equal quarterly installments.

SEC source: 0001144204-17-065647 · tv482219_4.xml · derivative · entry 4

Ward Robert · CIK 0001595111 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 640,785

Underlying: Common Stock · 640,785 shares

Expires 2027-12-26

F5 · derivative.exercise_date: The time-vesting options vest and become exercisable over a four (4) year period commencing on the Effective Date, with one-third (1/3) of the shares of common stock underlying the options vesting on December 26, 2018, with an additional one-twelfth (1/12) of the shares underlying the options vesting on each quarterly anniversary of the Effective Date over the course of three (3) years, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer; provided that vesting will be accelerated following the achievement of certain milestones.

SEC source: 0001144204-17-065647 · tv482219_4.xml · derivative · entry 3

Ward Robert · CIK 0001595111 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 640,785

Underlying: Common Stock · 640,785 shares

Expires 2027-12-26

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

F4 · derivative.exercise_date: The time-vesting restricted stock units vest and become exercisable over a four (4) year period commencing on December 26, 2017 (the "Effective Date"), with one-third (1/3) of the units vesting on December 26, 2018, with an additional one-twelfth (1/12) of the units vesting on each quarterly anniversary of the Effective Date over the course of three (3) years, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer; provided that vesting will be accelerated following the achievement of certain milestones.

SEC source: 0001144204-17-065647 · tv482219_4.xml · derivative · entry 2

Ward Robert · CIK 0001595111 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,427

Underlying: Common Stock · 22,427 shares

Expires 2027-12-26

F3 · derivative.exercise_date: The performance stock options vest and become immediately exercisable upon the date that marks the Issuer's first successful completion of a Phase-2B study with respect to any indication, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.

SEC source: 0001144204-17-065647 · tv482219_4.xml · derivative · entry 1

Ward Robert · CIK 0001595111 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,427

Underlying: Common Stock · 22,427 shares

Expires 2027-12-26

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

F2 · derivative.exercise_date: The performance restricted stock units vest and become immediately exercisable upon the date that marks the Issuer's first successful completion of a Phase-2B study with respect to any indication, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.

SEC source: 0001144204-17-065040 · tv482001_4.xml · derivative · entry 1

WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 399,266

Underlying: Common Stock · 399,266 shares

Expires 2027-12-20

F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on December 20, 2017, with one fourth of the shares of common stock underlying the options vesting on December 20, 2018, and the remainder vests in twelve equal quarterly installments thereafter.

SEC source: 0001209191-18-012960 · doc4a.xml · derivative · entry 1

WEAVER GREGORY L · CIK 0001251779 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 399,266

Underlying: Common Stock · 399,266 shares

Expires 2027-12-19

F1 · derivative.exercise_price: The initial Form 4 filed on December 22, 2017, by the Reporting Person inadvertently overstated the exercise price of the option.

F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on December 20, 2017, with one fourth of the shares of common stock underlying the options vesting on December 20, 2018, and the remainder vests in twelve equal quarterly installments thereafter.

SEC source: 0001144204-17-064888 · tv481925_4.xml · derivative · entry 1

FROST PHILLIP MD ET AL · CIK 0000898860 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,621

Underlying: Common Stock · 3,621 shares

Expires 2027-12-19

F1 · price: Such options were granted to Dr. Frost under Sevion Therapeutics Inc.'s ("Sevion's") 2008 Incentive Compensation Plan for services performed during Sevion's fiscal year ended June 30, 2017 and the portion of Sevion's fiscal year ended June 30, 2018 leading up to the closing of Sevion's transaction with Eloxx Pharmaceuticals, Ltd. (the "Transaction"), which occurred on December 19, 2017. In connection with the closing of the Transaction, Sevion effected a 1-for-20 reverse stock split and changed its corporate name to "Eloxx Pharmaceuticals, Inc." Such options were granted on a post-split basis and are immediately exercisable at an exercise price of $6.00 per share, which is equal to the closing selling price of Sevion's common stock on December 19, 2017, as reflected on a post-split basis.

SEC source: 0001209191-17-066864 · doc4.xml · nonDerivative · entry 1

Opko Health, Inc. · CIK 0000944809 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,289,818

F1 · shares: On December 19, 2017, the Issuer, Sevion Sub Ltd. ("Acquisition Sub"), and Eloxx Pharmaceuticals Ltd. ("Eloxx"), completed the merger contemplated under that certain Merger Agreement dated May 31, 2017, and pursuant to which Acquisition Sub merged with and into Eloxx, with Eloxx becoming the surviving corporation and a wholly-owned subsidiary of the Issuer. At the effective time of the merger, shares held by existing Eloxx shareholders prior to the Merger was converted, on a pro rata basis, into the right to receive 20,316,656 shares of Issuer common stock, after giving effect to a 1-for-20 reverse stock split that was effected on December 19, 2017.

F1 · price: On December 19, 2017, the Issuer, Sevion Sub Ltd. ("Acquisition Sub"), and Eloxx Pharmaceuticals Ltd. ("Eloxx"), completed the merger contemplated under that certain Merger Agreement dated May 31, 2017, and pursuant to which Acquisition Sub merged with and into Eloxx, with Eloxx becoming the surviving corporation and a wholly-owned subsidiary of the Issuer. At the effective time of the merger, shares held by existing Eloxx shareholders prior to the Merger was converted, on a pro rata basis, into the right to receive 20,316,656 shares of Issuer common stock, after giving effect to a 1-for-20 reverse stock split that was effected on December 19, 2017.

SEC source: 0001144204-17-064890 · tv481927_4.xml · derivative · entry 1

RECTOR DAVID · CIK 0001167113 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,500

Underlying: Common Stock · 27,500 shares

Expires 2027-12-19

F1 · price: Such options were granted to Mr. Rector under Sevion Therapeutics Inc.'s ("Sevion's") 2008 Incentive Compensation Plan for services performed during Sevion's fiscal year ended June 30, 2017 and the portion of Sevion's fiscal year ended June 30, 2018 leading up to the closing of Sevion's transaction with Eloxx Pharmaceuticals, Ltd. (the "Transaction"), which occurred on December 19, 2017. In connection with the closing of the Transaction, Sevion effected a 1-for-20 reverse stock split and changed its corporate name to "Eloxx Pharmaceuticals, Inc." Such options were granted on a post-split basis and are immediately exercisable at an exercise price of $6.00 per share, which is equal to the closing selling price of Sevion's common stock on December 19, 2017, as reflected on a post-split basis.

SEC source: 0001144204-17-064889 · tv481926_4.xml · derivative · entry 1

BRACA JOHN N · CIK 0001267249 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,190

Underlying: Common Stock · 18,190 shares

Expires 2027-12-19

F1 · price: Such options were granted to Mr. Braca under Sevion Therapeutics Inc.'s ("Sevion's") 2008 Incentive Compensation Plan for services performed during Sevion's fiscal year ended June 30, 2017 and the portion of Sevion's fiscal year ended June 30, 2018 leading up to the closing of Sevion's transaction with Eloxx Pharmaceuticals, Ltd. (the "Transaction"), which occurred on December 19, 2017. In connection with the closing of the Transaction, Sevion effected a 1-for-20 reverse stock split and changed its corporate name to "Eloxx Pharmaceuticals, Inc." Such options were granted on a post-split basis and are immediately exercisable at an exercise price of $6.00 per share, which is equal to the closing selling price of Sevion's common stock on December 19, 2017, as reflected on a post-split basis.

SEC source: 0001144204-17-064887 · tv481924_4.xml · derivative · entry 1

Rubin Steven D · CIK 0001381874 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,189

Underlying: Common Stock · 43,189 shares

Expires 2027-12-19

F1 · price: Such options were granted to Mr. Rubin under Sevion Therapeutics Inc.'s ("Sevion's") 2008 Incentive Compensation Plan for services performed during Sevion's fiscal year ended June 30, 2017 and the portion of Sevion's fiscal year ended June 30, 2018 leading up to the closing of Sevion's transaction with Eloxx Pharmaceuticals, Ltd. (the "Transaction"), which occurred on December 19, 2017. In connection with closing of the Transaction, Sevion effected a 1-for-20 reverse stock split and changed its corporate name to "Eloxx Pharmaceuticals, Inc." Such options were granted on a post-split basis and are immediately exercisable at an exercise price of $6.00 per share, which is equal to the closing selling price of Sevion's common stock on December 19, 2017, as reflected on a post-split basis.

SEC source: 0001209191-17-059592 · doc4.xml · derivative · entry 2

Opko Health, Inc. · CIK 0000944809 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,250,006 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: The derivative security was previously subject to a "blocker" pursuant to which the reporting person was unable to convert the derivative security to the extent such conversion would result in the reporting person owning more than 4.99%.

F3 · derivative.exercise_date: The convertible preferred stock was convertible at any time at the holder's option and had no expiration date.

F3 · derivative.expiration_date: The convertible preferred stock was convertible at any time at the holder's option and had no expiration date.

SEC source: 0001209191-17-059592 · doc4.xml · nonDerivative · entry 1

Opko Health, Inc. · CIK 0000944809 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,893,844

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Reporting Person converted 66,667 shares of 0% Series C Convertible Preferred Stock on September 19, 2017 at a conversion price of $.40 per share, resulting in the acquisition of 1,250,006 shares of Common Stock. The conversion was effected in connection with that certain proposed merger between the Issuer, Sevion Sub Ltd. ("Acquisition Sub"), and Eloxx Pharmaceuticals Ltd. ("Eloxx"), pursuant to which, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement dated May 31, 2017, Acquisition Sub will merge with and into Eloxx, with Eloxx becoming the surviving corporation and a wholly-owned subsidiary of the Issuer.

SEC source: 0001209191-17-048791 · doc4.xml · derivative · entry 4

Opko Health, Inc. · CIK 0000944809 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500,000 shares

Expires 2017-08-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: The derivative security was previously subject to a "blocker" pursuant to which the reporting person was unable to convert the derivative security to the extent such conversion would result in the reporting person owning more than 4.99%.

F2 · kind: Pursuant to the terms of the Convertible Note, the Reporting Person acquired (i) 2,500,000 shares of Common Stock upon conversion of $250,000 in principal amount of the Convertible Note, and (ii) 63,699 shares of Common Stock in accrued and previously unpaid interest thereon (6,369.86).

SEC source: 0001209191-17-048791 · doc4.xml · derivative · entry 3

Opko Health, Inc. · CIK 0000944809 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,500,000 shares

Expires 2017-11-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: The derivative security was previously subject to a "blocker" pursuant to which the reporting person was unable to convert the derivative security to the extent such conversion would result in the reporting person owning more than 4.99%.

F1 · kind: Pursuant to the terms of the Convertible Note, the Reporting Person acquired (i) 1,500,000 shares of Common Stock upon conversion of $150,000 in principal amount of the Convertible Note, and (ii) 63,123 shares of Common Stock in accrued and previously unpaid interest thereon ($6,312.33).

SEC source: 0001209191-17-048791 · doc4.xml · nonDerivative · entry 2

Opko Health, Inc. · CIK 0000944809 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,643,838

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Pursuant to the terms of the Convertible Note, the Reporting Person acquired (i) 2,500,000 shares of Common Stock upon conversion of $250,000 in principal amount of the Convertible Note, and (ii) 63,699 shares of Common Stock in accrued and previously unpaid interest thereon (6,369.86).

SEC source: 0001209191-17-048791 · doc4.xml · nonDerivative · entry 1

Opko Health, Inc. · CIK 0000944809 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,080,139

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the Convertible Note, the Reporting Person acquired (i) 1,500,000 shares of Common Stock upon conversion of $150,000 in principal amount of the Convertible Note, and (ii) 63,123 shares of Common Stock in accrued and previously unpaid interest thereon ($6,312.33).

SEC source: 0001144204-17-009647 · v459867_form4.xml · derivative · entry 1

FROST PHILLIP MD ET AL · CIK 0000898860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,091

Underlying: Common Stock · 109,091 shares

Expires 2027-02-14

F1 · shares: Such options were granted to Dr. Frost in lieu of cash compensation under the Company's independent director compensation plan and are immediately exercisable.

SEC source: 0001144204-17-009645 · v459866_form4.xml · derivative · entry 1

BRACA JOHN N · CIK 0001267249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,045

Underlying: Common Stock · 167,045 shares

Expires 2027-02-14

F1 · shares: Such options were granted to Mr. Braca in lieu of cash compensation under the Company's independent director compensation plan and are immediately exercisable.

SEC source: 0001144204-17-009649 · v459869_form4.xml · derivative · entry 1

Rubin Steven D · CIK 0001381874 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,227

Underlying: Common Stock · 160,227 shares

Expires 2027-02-14

F1 · shares: Such options were granted to Mr. Rubin in lieu of cash compensation under the Company's independent director compensation plan and are immediately exercisable.